Xxcorxxheaxxhcaxx Inxx Pharmaceutical Import Profile — Canada (DGFT 2022–2026)

Name: Xxcorxxheaxxhcaxx Inxx Pharmaceutical Import Records from India — 3 Products, $400.0K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Xxcorxxheaxxhcaxx Inxx — Pharmaceutical Importer Profile (2026) | 3 Products, $400.0K Trade | TransData Nexus

Xxcorxxheaxxhcaxx Inxx

Pharmaceutical Importer · Canada · Oncology Focus · $400.0K Total Trade · DGFT Verified

Xxcorxxheaxxhcaxx Inxx is a pharmaceutical importer based in Canada with a total trade value of $400.0K across 3 products in 2 therapeutic categories. Based on 8 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Xxcorxxheaxxhcaxx Inxx sources from 1 verified Indian supplier, with Intas Pharmaceuticals Limited accounting for 100.0% of imports.

Xxcorxxheaxxhcaxx Inxx — Import Portfolio & Supplier Network

Xxcorxxheaxxhcaxx Inxx import network — 3 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Xxcorxxheaxxhcaxx Inxx?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Intas Pharmaceuticals Limited	$759.8K	17	100.0%

Xxcorxxheaxxhcaxx Inxx sources from 1 verified Indian supplier across 13 distinct formulations. The sourcing is highly concentrated — Intas Pharmaceuticals Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

Formulation	Value	Ships
Cisplatin injection BP-1MG/ML(100MG/100m	$100.0K	2
Capecitabine 500MG 1x120t	$100.0K	2
Cisplatin INJ 1 MG/ML 100 ML	$100.0K	2
Methotrexate 50MG/ML 0.50ML	$70.6K	2
Pemetrexed disodium 500	$50.0K	1
Carboplatin injection BP 600MG/60ML	$50.0K	1
Methotrexate 50MG/ML 0.30ML	$50.0K	1
Fluorouraci 50MG/ml100ml- INJ	$50.0K	1
Carboplatin INJ. BP 450MG/45ML 1x1v (e2)	$50.0K	1
Pemetrexed disodium 100	$48.0K	1
Oxaliplatin INJ 5MG/ML 10ML	$36.5K	1
Fluorouracil INJ-50MG/ML 100 ML	$35.8K	1
Capecitabine 150MG	$18.9K	1

Import Portfolio — Top 3 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Cisplatin	Oncology	$200.0K	4	1.6%	5
2	Carboplatin	Oncology	$100.0K	2	0.1%	18
3	Pemetrexed	Advanced Oncology	$100.0K	2	0.3%	15

Xxcorxxheaxxhcaxx Inxx imports 3 pharmaceutical products across 2 categories into Canada totaling $400.0K.

Xxcorxxheaxxhcaxx Inxx — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Xxcorxxheaxxhcaxx Inxx is a Canadian pharmaceutical importer specializing in the acquisition of finished pharmaceutical formulations from international suppliers, particularly from India. The company operates as a buyer within Canada's pharmaceutical distribution network, focusing on sourcing specific oncology medications to meet domestic healthcare needs. While the exact headquarters location and parent company details are not publicly disclosed, Xxcorxxheaxxhcaxx Inxx plays a pivotal role in ensuring the availability of critical cancer treatments in the Canadian market.

2Distribution Network

Specific details regarding Xxcorxxheaxxhcaxx Inxx's warehouse locations and logistics capabilities are not publicly available. However, as a pharmaceutical importer, the company is likely to collaborate with established distribution partners to ensure efficient storage and delivery of imported products across Canada. The distribution network would encompass major urban centers and healthcare facilities, ensuring timely access to essential oncology medications nationwide.

3Industry Role

Xxcorxxheaxxhcaxx Inxx functions primarily as a pharmaceutical importer within Canada's supply chain. By sourcing finished pharmaceutical formulations from international suppliers, the company bridges the gap between foreign manufacturers and the Canadian market, ensuring the availability of specialized medications not produced domestically. This role is crucial in maintaining a diverse and resilient pharmaceutical supply chain, particularly for niche therapeutic areas such as oncology.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Xxcorxxheaxxhcaxx Inxx

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Xxcorxxheaxxhcaxx Inxx demonstrates a high degree of supplier concentration, sourcing all its imported pharmaceutical products from a single supplier: INTAS Pharmaceuticals Limited. This single-source dependency could pose risks related to supply chain disruptions, such as production delays or regulatory challenges faced by the supplier. However, the consistent volume of shipments—17 in total—suggests a stable and well-established relationship between Xxcorxxheaxxhcaxx Inxx and INTAS Pharmaceuticals Limited. The strategic choice to concentrate sourcing from one supplier may be driven by factors such as product quality, cost-effectiveness, and reliability.

2Supply Chain Resilience

The resilience of Xxcorxxheaxxhcaxx Inxx's supply chain is closely tied to the stability and reliability of INTAS Pharmaceuticals Limited. The company's focus on importing finished pharmaceutical formulations indicates a preference for ready-to-market products, potentially reducing the complexity of the supply chain. However, the lack of publicly available information on backup suppliers and formulation diversity suggests a potential vulnerability to disruptions. To enhance supply chain resilience, it would be prudent for Xxcorxxheaxxhcaxx Inxx to consider diversifying its supplier base and exploring alternative formulations to mitigate risks associated with single-source dependency.

Importing Pharmaceuticals into Canada — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Canada

1Regulatory Authority & Framework

In Canada, the regulation of pharmaceutical products is overseen by Health Canada, the federal department responsible for national health policy and regulation. The primary legislation governing pharmaceutical imports is the Food and Drugs Act, which sets out the requirements for the importation, sale, and distribution of drugs within Canada. Under this Act, all drugs imported into Canada must be authorized for sale, ensuring they meet the necessary safety, efficacy, and quality standards. The regulatory framework also includes the Food and Drug Regulations, which provide detailed provisions on the importation process, labeling, and compliance requirements for pharmaceutical products.

2Import Licensing & GMP

Importers of pharmaceutical products into Canada must obtain a Drug Establishment License (DEL) from Health Canada. This license authorizes the importer to import, distribute, and wholesale drugs within Canada. Additionally, the foreign manufacturing site must be listed on the importer's DEL, ensuring that the manufacturing facility complies with Good Manufacturing Practices (GMP) as outlined in Part C, Division 2 of the Food and Drug Regulations. GMP compliance is essential to ensure that pharmaceutical products are consistently produced and controlled to the quality standards appropriate to their intended use.

Xxcorxxheaxxhcaxx Inxx — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Xxcorxxheaxxhcaxx Inxx's focus on importing oncology medications, specifically cisplatin, carboplatin, and pemetrexed, aligns with the significant demand for cancer treatments in Canada. The Canadian healthcare system continually seeks to provide patients with access to effective and affordable cancer therapies. By sourcing these specific products, Xxcorxxheaxxhcaxx Inxx addresses a critical need within the market, ensuring that healthcare providers have access to essential medications required for cancer treatment protocols.

2Sourcing Profile

Xxcorxxheaxxhcaxx Inxx's sourcing strategy is centered on importing finished pharmaceutical formulations from a single supplier, INTAS Pharmaceuticals Limited. This approach allows the company to maintain a streamlined procurement process and potentially negotiate favorable terms with the supplier. The focus on specific oncology medications indicates a targeted sourcing strategy aimed at fulfilling a niche market segment within the Canadian pharmaceutical industry.

3Market Positioning

By importing specialized oncology medications, Xxcorxxheaxxhcaxx Inxx serves a critical segment of the Canadian pharmaceutical market, supplying essential cancer treatments to healthcare providers. The company's role is pivotal in ensuring that patients have access to necessary therapies, thereby supporting the broader healthcare system's efforts in cancer care. This positioning underscores the importance of specialized importers in maintaining the diversity and resilience of the pharmaceutical supply chain.

Seller's Guide — How to Become a Supplier to Xxcorxxheaxxhcaxx Inxx

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter the Canadian market by meeting the specific quality standards and regulatory requirements set by Health Canada. By obtaining the necessary certifications and approvals, Indian exporters can position themselves as alternative suppliers to Xxcorxxheaxxhcaxx Inxx, potentially diversifying the importer's supplier base and reducing dependency on a single source. This diversification can enhance supply chain resilience and provide Canadian healthcare providers with a broader range of options for sourcing oncology medications.

2Requirements & Qualifications

Indian exporters seeking to supply pharmaceutical products to Xxcorxxheaxxhcaxx Inxx and the Canadian market must ensure that their manufacturing facilities comply with Good Manufacturing Practices (GMP) as recognized by Health Canada. Additionally, they must obtain the necessary certifications, such as a Drug Establishment License (DEL) from Health Canada, and ensure that their products have a Drug Identification Number (DIN). Compliance with these regulatory requirements is essential to gain market access and establish a successful partnership with Canadian importers.

How to Approach

Frequently Asked Questions — Xxcorxxheaxxhcaxx Inxx

What products does Xxcorxxheaxxhcaxx Inxx import from India?

Xxcorxxheaxxhcaxx Inxx imports 3 pharmaceutical products across 2 categories. Top imports: Cisplatin ($200.0K), Carboplatin ($100.0K), Pemetrexed ($100.0K).

Who supplies pharmaceuticals to Xxcorxxheaxxhcaxx Inxx from India?

Xxcorxxheaxxhcaxx Inxx sources from 1 verified Indian suppliers. The primary supplier is Intas Pharmaceuticals Limited (100.0% of imports, $759.8K).

What is Xxcorxxheaxxhcaxx Inxx's total pharmaceutical import value?

Xxcorxxheaxxhcaxx Inxx's total pharmaceutical import value from India is $400.0K, based on 8 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Xxcorxxheaxxhcaxx Inxx focus on?

Xxcorxxheaxxhcaxx Inxx imports across 2 categories. The largest: Oncology (75.0%), Advanced Oncology (25.0%).

Get Full Xxcorxxheaxxhcaxx Inxx Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.